-The Hindu Tackling TB requires both strengthening the public sector and engaging the private sector Over 60 per cent of all Indians seek health care in the private sector according to India's last National Family Health Survey. This undoubtedly makes the private sector the largest provider of health services in India. The government health system, though vast and well-intentioned, continues to be overburdened with multiple challenges including long waiting hours, an ageing...

-The Hindu   It is creditable that Narendra Modi seeks inspiration for his growth model from China and Japan rather than the U.S., which is a high-cost, specialist-driven model The old adage ‘health is wealth' was given legitimacy by no less a personage than Professor Jeffrey Sachs, who in 2000, chaired the World Health Organization's Commission on Macroeconomics and Health (CMH). The CMH report brought forth indisputable evidence of the link between health,...

-The Hindu A strong whistle-blower protection law in India would expose financial corruption in a way that reinforces ethical business practices In 2013, generic pharmaceutical company Ranbaxy pleaded guilty to seven criminal felonies for drug manufacturing fraud and agreed to cough up an unprecedented $500 million in fines. The case against Ranbaxy was significant not only for being a successful prosecution of a powerful India corporation. It also marked the triumph of Dinesh...

-The Hindu Unless a deeper, institutional change is ushered in to break the nexus between drug companies and the regulatory regime, Indians consuming drugs may be exposing themselves to serious risks Even before I walked into the Mayflower Hotel in the heart of Washington on a crisp autumn afternoon to meet Dinesh Thakur, whistle-blower and former director of India-based pharmaceutical giant Ranbaxy, I had a hunch that this conversation would spark some...

-Live Mint Apex court expresses concerns about drug trials being permitted on humans without comprehensive rules to regulate the approval process New Delhi: The apex court on Monday directed the health ministry to justify its approval for 162 global clinical trials in India, increasing the uncertainty faced by the nation's $500 million clinical research industry. The Supreme Court expressed its concerns about drug trials being permitted on humans without comprehensive rules to...